News – Page 861 – Endpoints News

Coronavirus update: A summit in Geneva, WuXi hunts antibodies and J&J partners on a vaccine search

6 years ago

Corey Goodman marshals $105M mega-round for his CD47 upstart, looking to break new ground in PhII

6 years ago

Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer

6 years ago

New Sanofi chief Paul Hudson takes the ax to his executive committee, chopping 4 key players

6 years ago

Lilly, Novo Nordisk fight insulin biosimilars with tweaks to FDA draft guidance

6 years ago

Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease ...

6 years ago

Ligand buys its way into partnership with Roche, CF Foundation — plus some ion channel tech once owned by Pfizer

6 years ago

Bayer hands over a big drug R&D operation to CRO amid an ongoing restructuring effort

6 years ago

A Chinese company is already mass producing Gilead's experimental coronavirus drug

6 years ago

The Wuhan coronavirus has an official name: COVID-19; Revolution Medicines upsizes IPO terms

6 years ago

Agios' Lewis Cantley returns with a new company and, he claims, a major oncological discovery

6 years ago

Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug

6 years ago

Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs

6 years ago

Upstart cancer biotech recruits a top Pfizer oncology researcher as CSO — could an IPO be far behind?

6 years ago

Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish ...

6 years ago

Moderna eyes $500M secondary offering on upbeat coronavirus vaccine update — almost ready for the clinic

6 years ago

Merck walks away from KalVista, who turns their sights on HAE

6 years ago

Trump’s 2021 budget request seeks modest funding increase for FDA

6 years ago

FDA slaps a hold on LogicBio and its gene editing plans — shares tumble

6 years ago

With blockbuster dreams, Exelixis is looking for some redemption for cabo in prostate cancer. It won’t be easy

6 years ago

Vivek Ramaswamy's Arbutus kills another program over safety, stock takes another hit

6 years ago

Are priority review voucher programs stimulating drug development? The data suggest not really, finds GAO report

6 years ago

Eye drop developer Oculis showcases positive PhII data; Aquestive hunts for another FDA OK

6 years ago

Science team designs a new CAR they say may work much better than BCMAs in fighting multiple myeloma

6 years ago

First page Previous page 858 859 860861862 863 864 Next page Last page